Case Report: Long-term survival in extensive-stage small cell lung cancer treated with adebrelimab-based combination therapy
The integration of immune checkpoint inhibitors into first-line treatment has markedly improved outcomes for extensive-stage small cell lung cancer (ES-SCLC). Adebrelimab, a PD-L1 inhibitor, demonstrated superior overall survival in the phase 3 CAPSTONE-1 trial. We present a detailed case of a 62-ye...
Enregistré dans:
| Auteurs principaux: | , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Frontiers Media S.A.
2026-07-01
|
| Collection: | Frontiers in Oncology |
| Sujets: | |
| Accès en ligne: | https://www.frontiersin.org/articles/10.3389/fonc.2026.1854258/full |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|